Literature DB >> 34780722

Integrative Analysis of the Inflammatory Bowel Disease Serum Metabolome Improves Our Understanding of Genetic Etiology and Points to Novel Putative Therapeutic Targets.

Antonio F Di'Narzo1, Sander M Houten2, Roman Kosoy2, Ruiqi Huang3, Frédéric M Vaz4, Ruixue Hou3, Gabrielle Wei2, Wenhui Wang2, Phillip H Comella2, Tetyana Dodatko2, Eduard Rogatsky2, Aleksandar Stojmirovic5, Carrie Brodmerkel5, Jacqueline Perrigoue5, Amy Hart5, Mark Curran5, Joshua R Friedman5, Jun Zhu6, Manasi Agrawal7, Judy Cho7, Ryan Ungaro7, Marla C Dubinsky7, Bruce E Sands7, Mayte Suárez-Fariñas8, Eric E Schadt6, Jean-Frédéric Colombel7, Andrew Kasarskis9, Ke Hao6, Carmen Argmann10.   

Abstract

BACKGROUND & AIMS: Polygenic and environmental factors are underlying causes of inflammatory bowel disease (IBD). We hypothesized that integration of the genetic loci controlling a metabolite's abundance, with known IBD genetic susceptibility loci, may help resolve metabolic drivers of IBD.
METHODS: We measured the levels of 1300 metabolites in the serum of 484 patients with ulcerative colitis (UC) and 464 patients with Crohn's disease (CD) and 365 controls. Differential metabolite abundance was determined for disease status, subtype, clinical and endoscopic disease activity, as well as IBD phenotype including disease behavior, location, and extent. To inform on the genetic basis underlying metabolic diversity, we integrated metabolite and genomic data. Genetic colocalization and Mendelian randomization analyses were performed using known IBD risk loci to explore whether any metabolite was causally associated with IBD.
RESULTS: We found 173 genetically controlled metabolites (metabolite quantitative trait loci, 9 novel) within 63 non-overlapping loci (7 novel). Furthermore, several metabolites significantly associated with IBD disease status and activity as defined using clinical and endoscopic indexes. This constitutes a resource for biomarker discovery and IBD biology insights. Using this resource, we show that a novel metabolite quantitative trait locus for serum butyrate levels containing ACADS was not supported as causal for IBD; replicate the association of serum omega-6 containing lipids with the fatty acid desaturase 1/2 locus and identify these metabolites as causal for CD through Mendelian randomization; and validate a novel association of serum plasmalogen and TMEM229B, which was predicted as causal for CD.
CONCLUSIONS: An exploratory analysis combining genetics and unbiased serum metabolome surveys can reveal novel biomarkers of disease activity and potential mediators of pathology in IBD.
Copyright © 2022 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Differential Metabolite Abundance Analysis; Inflammatory Bowel Disease; Mendelian Randomization; Metabolome

Mesh:

Substances:

Year:  2021        PMID: 34780722      PMCID: PMC9214725          DOI: 10.1053/j.gastro.2021.11.015

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   33.883


  45 in total

1.  Biomarker discovery for inflammatory bowel disease, using proteomic serum profiling.

Authors:  Marie-Alice Meuwis; Marianne Fillet; Pierre Geurts; Dominique de Seny; Laurence Lutteri; Jean-Paul Chapelle; Vincent Bours; Louis Wehenkel; Jacques Belaiche; Michel Malaise; Edouard Louis; Marie-Paule Merville
Journal:  Biochem Pharmacol       Date:  2006-12-20       Impact factor: 5.858

Review 2.  Mendelian randomization as an instrumental variable approach to causal inference.

Authors:  Vanessa Didelez; Nuala Sheehan
Journal:  Stat Methods Med Res       Date:  2007-08       Impact factor: 3.021

Review 3.  The Treatment of Inflammatory Bowel Disease in Patients with Selected Primary Immunodeficiencies.

Authors:  Dror S Shouval; Matthew Kowalik; Scott B Snapper
Journal:  J Clin Immunol       Date:  2018-06-29       Impact factor: 8.317

4.  Interactions between the dietary polyunsaturated fatty acid ratio and genetic factors determine susceptibility to pediatric Crohn's disease.

Authors:  Irina Costea; David R Mack; Rozenn N Lemaitre; David Israel; Valerie Marcil; Ali Ahmad; Devendra K Amre
Journal:  Gastroenterology       Date:  2014-01-07       Impact factor: 22.682

5.  Plasma polyunsaturated fatty acid pattern in active inflammatory bowel disease.

Authors:  M Esteve-Comas; M Ramírez; F Fernández-Bañares; A Abad-Lacruz; A Gil; E Cabré; F González-Huix; J Moreno; P Humbert; M Guilera
Journal:  Gut       Date:  1992-10       Impact factor: 23.059

6.  Genetic studies of urinary metabolites illuminate mechanisms of detoxification and excretion in humans.

Authors:  Pascal Schlosser; Yong Li; Peggy Sekula; Johannes Raffler; Franziska Grundner-Culemann; Maik Pietzner; Yurong Cheng; Matthias Wuttke; Inga Steinbrenner; Ulla T Schultheiss; Fruzsina Kotsis; Tim Kacprowski; Lukas Forer; Birgit Hausknecht; Arif B Ekici; Matthias Nauck; Uwe Völker; Gerd Walz; Peter J Oefner; Florian Kronenberg; Robert P Mohney; Michael Köttgen; Karsten Suhre; Kai-Uwe Eckardt; Gabi Kastenmüller; Anna Köttgen
Journal:  Nat Genet       Date:  2020-01-20       Impact factor: 38.330

7.  Alterations in Lipid, Amino Acid, and Energy Metabolism Distinguish Crohn's Disease from Ulcerative Colitis and Control Subjects by Serum Metabolomic Profiling.

Authors:  Elizabeth A Scoville; Margaret M Allaman; Caroline T Brown; Amy K Motley; Sara N Horst; Christopher S Williams; Tatsuki Koyama; Zhiguo Zhao; Dawn W Adams; Dawn B Beaulieu; David A Schwartz; Keith T Wilson; Lori A Coburn
Journal:  Metabolomics       Date:  2017-12-29       Impact factor: 4.290

Review 8.  Heritability estimates for 361 blood metabolites across 40 genome-wide association studies.

Authors:  Fiona A Hagenbeek; René Pool; Jenny van Dongen; Harmen H M Draisma; Jouke Jan Hottenga; Gonneke Willemsen; Abdel Abdellaoui; Iryna O Fedko; Anouk den Braber; Pieter Jelle Visser; Eco J C N de Geus; Ko Willems van Dijk; Aswin Verhoeven; H Eka Suchiman; Marian Beekman; P Eline Slagboom; Cornelia M van Duijn; Amy C Harms; Thomas Hankemeier; Meike Bartels; Michel G Nivard; Dorret I Boomsma
Journal:  Nat Commun       Date:  2020-01-07       Impact factor: 14.919

9.  Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease.

Authors:  Luke Jostins; Stephan Ripke; Rinse K Weersma; Richard H Duerr; Dermot P McGovern; Ken Y Hui; James C Lee; L Philip Schumm; Yashoda Sharma; Carl A Anderson; Jonah Essers; Mitja Mitrovic; Kaida Ning; Isabelle Cleynen; Emilie Theatre; Sarah L Spain; Soumya Raychaudhuri; Philippe Goyette; Zhi Wei; Clara Abraham; Jean-Paul Achkar; Tariq Ahmad; Leila Amininejad; Ashwin N Ananthakrishnan; Vibeke Andersen; Jane M Andrews; Leonard Baidoo; Tobias Balschun; Peter A Bampton; Alain Bitton; Gabrielle Boucher; Stephan Brand; Carsten Büning; Ariella Cohain; Sven Cichon; Mauro D'Amato; Dirk De Jong; Kathy L Devaney; Marla Dubinsky; Cathryn Edwards; David Ellinghaus; Lynnette R Ferguson; Denis Franchimont; Karin Fransen; Richard Gearry; Michel Georges; Christian Gieger; Jürgen Glas; Talin Haritunians; Ailsa Hart; Chris Hawkey; Matija Hedl; Xinli Hu; Tom H Karlsen; Limas Kupcinskas; Subra Kugathasan; Anna Latiano; Debby Laukens; Ian C Lawrance; Charlie W Lees; Edouard Louis; Gillian Mahy; John Mansfield; Angharad R Morgan; Craig Mowat; William Newman; Orazio Palmieri; Cyriel Y Ponsioen; Uros Potocnik; Natalie J Prescott; Miguel Regueiro; Jerome I Rotter; Richard K Russell; Jeremy D Sanderson; Miquel Sans; Jack Satsangi; Stefan Schreiber; Lisa A Simms; Jurgita Sventoraityte; Stephan R Targan; Kent D Taylor; Mark Tremelling; Hein W Verspaget; Martine De Vos; Cisca Wijmenga; David C Wilson; Juliane Winkelmann; Ramnik J Xavier; Sebastian Zeissig; Bin Zhang; Clarence K Zhang; Hongyu Zhao; Mark S Silverberg; Vito Annese; Hakon Hakonarson; Steven R Brant; Graham Radford-Smith; Christopher G Mathew; John D Rioux; Eric E Schadt; Mark J Daly; Andre Franke; Miles Parkes; Severine Vermeire; Jeffrey C Barrett; Judy H Cho
Journal:  Nature       Date:  2012-11-01       Impact factor: 49.962

10.  Gut microbiota density influences host physiology and is shaped by host and microbial factors.

Authors:  Eduardo J Contijoch; Graham J Britton; Chao Yang; Ilaria Mogno; Zhihua Li; Ruby Ng; Sean R Llewellyn; Sheela Hira; Crystal Johnson; Keren M Rabinowitz; Revital Barkan; Iris Dotan; Robert P Hirten; Shih-Chen Fu; Yuying Luo; Nancy Yang; Tramy Luong; Philippe R Labrias; Sergio Lira; Inga Peter; Ari Grinspan; Jose C Clemente; Roman Kosoy; Seunghee Kim-Schulze; Xiaochen Qin; Anabella Castillo; Amanda Hurley; Ashish Atreja; Jason Rogers; Farah Fasihuddin; Merjona Saliaj; Amy Nolan; Pamela Reyes-Mercedes; Carina Rodriguez; Sarah Aly; Kenneth Santa-Cruz; Lauren Peters; Mayte Suárez-Fariñas; Ruiqi Huang; Ke Hao; Jun Zhu; Bin Zhang; Bojan Losic; Haritz Irizar; Won-Min Song; Antonio Di Narzo; Wenhui Wang; Benjamin L Cohen; Christopher DiMaio; David Greenwald; Steven Itzkowitz; Aimee Lucas; James Marion; Elana Maser; Ryan Ungaro; Steven Naymagon; Joshua Novak; Brijen Shah; Thomas Ullman; Peter Rubin; James George; Peter Legnani; Shannon E Telesco; Joshua R Friedman; Carrie Brodmerkel; Scott Plevy; Judy H Cho; Jean-Frederic Colombel; Eric E Schadt; Carmen Argmann; Marla Dubinsky; Andrew Kasarskis; Bruce Sands; Jeremiah J Faith
Journal:  Elife       Date:  2019-01-22       Impact factor: 8.140

View more
  1 in total

Review 1.  The metabolic nature of inflammatory bowel diseases.

Authors:  Timon E Adolph; Moritz Meyer; Julian Schwärzler; Lisa Mayr; Felix Grabherr; Herbert Tilg
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-07-29       Impact factor: 73.082

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.